Please login to the form below

Not currently logged in
Email:
Password:

New NHS specialist cancer unit

Cancer campaigners welcome policy to invest in the treatment of brain and spinal cord tumours

Cancer charities have welcomed a move by ministers in England to increase investment in specialist cancer care for brain and spinal cord tumours.

Under ministerial proposals, hospitals will be invited to bid to become the first national centre for proton therapy – a cancer treatment that uses radiation to attack cancerous cells while minimising damage to nearby tissue. It works by firing energy into the tumour where electrons damage the DNA of cancerous cells, killing them.

There is just one specialist unit in England and it treats only less complex eye cancers. Clatterbridge on the Wirral uses a low-energy machine that can only be used to reach cancers near the eye. As a result, many patients are forced to seek care abroad.

Proton therapy, which is most commonly used on children and patients with tumours near the most sensitive parts of the brain and spinal cord, is available in the US and other European countries. However, the cost of treatment can be in excess of £100,000.

The new unit in England would treat up to 400 patients each year.

Wendy Fulcher, chairman of cancer charity, Brain Tumour Research, welcomed the news, saying that she hopes the move will "signal a shift in policy for increased funding for brain tumour treatment and research".

19th August 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics